Evan Kessler, DO
Family Medicine · Lansdale, PANPI 1164428645
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,524 of the $5,736 with a category attached, or 78.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,912 and has fallen 97.7% since, to $66 in 2025.
Across 262 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- AbbVie$563
- Amgen$507
- Pfizer$408
- W. L. Gore & Associates, Inc.$354
- Merck$354
- plus $2K from 30 others
Across 26 payments — averaging $10,127 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$254K
- Pfizer$10K
What the payments were for
- Travel & lodging$84615%
- Food & beverage$4,52479%
- Education$3666%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $1,221 |
| AbbVie(2 entities) | 34 | $563 |
| Amgen | 22 | $507 |
| Pfizer | 30 | $408 |
| W. L. Gore & Associates, Inc. | 1 | $354 |
| Merck | 29 | $354 |
| Johnson & Johnson(2 entities) | 19 | $262 |
| Sanofi-aventis U.S. LLC | 12 | $207 |
| Biohaven Pharmaceuticals, Inc. | 6 | $188 |
| AstraZeneca | 14 | $182 |
| Daiichi Sankyo Inc. | 10 | $180 |
| Amarin Pharma, Inc. | 10 | $169 |
| Novo Nordisk | 8 | $127 |
| Sunovion Pharmaceuticals Inc. | 7 | $95 |
| Sun Pharmaceutical Industries Inc. | 4 | $88 |
| GSK | 6 | $85 |
| Lilly USA, LLC | 5 | $77 |
| Alk-abello, Inc | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $55 |
| Abbott | 3 | $54 |
| Exact Sciences | 3 | $52 |
| Eisai Inc. | 3 | $44 |
| Circassia Inc. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Biofire Diagnostics, LLC | 1 | $35 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Novartis | 2 | $31 |
| Radius Health, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Clarus Therapeutics Inc. | 1 | $20 |
| Philips North America LLC | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $12 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,736 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 15 | $358,932 |
| OzempicSemaglutide | 103 | $98,804 |
| JanuviaSitagliptin Phosphate | 60 | $71,005 |
| EliquisApixaban | 79 | $66,327 |
| JardianceEmpagliflozin | 45 | $47,609 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $44,532 |
| MyrbetriqMirabegron | 47 | $41,608 |
| TrulicityDulaglutide | 27 | $28,338 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $25,574 |
| LinzessLinaclotide | 17 | $21,423 |
| ProliaDenosumab | 12 | $20,894 |
| XareltoRivaroxaban | 21 | $15,883 |
| FarxigaDapagliflozin Propanediol | 12 | $12,797 |
| MounjaroTirzepatide | 12 | $12,422 |
| TradjentaLinagliptin | 16 | $10,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Hetlioz | $14 | $358,93215 claims |
| Novo NordiskOzempic | $127 | $98,804103 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $85 | $79,851122 claims |
| MerckJanuvia | $354 | $71,00560 claims |
| PfizerEliquis | $408 | $66,32779 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $77 | $40,76039 claims |
| AbbVieLinzess, Synthroid | $563 | $23,68557 claims |
| AmgenProlia | $507 | $20,89412 claims |
| Johnson & JohnsonXarelto | $262 | $15,88321 claims |
| AstraZenecaFarxiga | $182 | $12,79712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Lansdale
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.